echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Corium Donepezil transdermal patch Adlarity new drug application is expected to be approved next year

    Corium Donepezil transdermal patch Adlarity new drug application is expected to be approved next year

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 12, 2021, Corium announced that the US FDA has set the new drug application (NDA) PDUFA target date for its donepezil (donepezil) transdermal patch Adlarity to March 11, 2022 for the treatment of mild/medium/ Patients with dementia caused by severe Alzheimer's disease


    According to statistics from the World Health Organization, more than 55 million people worldwide suffer from dementia, and Alzheimer's disease accounts for approximately 60%-70% of these patients


    Donepezil is a common cholinesterase inhibitor (cholinesterase inhibitors)


    Adlarity is a transdermal preparation of donepezil, made using Corium's proprietary Corplex technology platform


    With the slow and stable release of donepezil, the Adlarity transdermal system can regularly deliver the drug through the skin.


    Reference materials:

    [1] Corium Receives March 11, 2022 PDUFA Date for New Drug Application for Adlarity® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.